GDC 0879

Biological Activity for GDC 0879

Technical Data for GDC 0879

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility for GDC 0879

References for GDC 0879

References are publications that support the biological activity of the product.

• Hatzivassiliou et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature, 2010;464:431 PMID: 20130576
• Hoeflich et al. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAF^V600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res., 2009;69:3042 PMID: 19276360
• Wong et al. Pharmacodynamics of 2-{4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl}ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic conc J.Pharmacol.Exp.Ther., 2009;329:360 PMID: 19147858